Nucala 100 MG/ML syringeml
Ended Awarded
- Contract number
- SPE2DB25FL1S9
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $37,858
Award facts
- Contract value 100% obligated
- $37,858.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was awarded a $37,858 firm fixed-price delivery order by the Defense Logistics Agency (DLA) on August 13, 2025, for the supply of Nucala 100 mg/mL syringes. The contract, which has no set-aside designation, is scheduled for ultimate completion by August 14, 2025, and will be performed at the awardee's facility in Park Ridge, Illinois. This delivery order is issued under DMS Pharmaceutical Group's larger single-award Indefinite Delivery Contract with the DLA under the SPE2DB program, valued at $499,999,999 and valid through November 2026, which authorizes the issuance of firm fixed-price delivery orders for a comprehensive range of pharmaceutical items supporting military health facilities worldwide.
Nucala (mepolizumab) is a biologic medication used in the treatment of eosinophilic asthma and related conditions, representing a specialized pharmaceutical product within the DLA's broader medical supply procurement portfolio. DMS Pharmaceutical Group's award continues its established role as a critical supplier in the federal pharmaceutical supply chain, leveraging its capabilities to provide direct distribution of prescription drugs and biologics to Department of Defense healthcare sites across the military health system.
Quick answers
Who was awarded contract SPE2DB25FL1S9?
SPE2DB25FL1S9 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on August 13, 2025.
How much is contract SPE2DB25FL1S9 worth?
The government has obligated $37,858 on SPE2DB25FL1S9.
Is contract SPE2DB25FL1S9 an order under another contract?
Yes. SPE2DB25FL1S9 is a delivery order under SPE2DB20D9331, an indefinite delivery contract.
Was contract SPE2DB25FL1S9 competed?
The extent of competition for SPE2DB25FL1S9 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award